Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Study of Atezolizumab + Bevacizumab in PD-L1 High Non-squamous NSCLC (Ancillary to WJOG10718L)
jRCT1080224072Phase 2Completed
- Sponsor
- Kaname Nosaki (Principal Investigator)
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Kaname Nosaki (Principal Investigator). Started Oct 2018; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080224072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224072.